Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Caprion Pharmaceuticals will collaborate with Boehringer Ingelheim to identify biomarkers of metabolic and inflammatory disease using Caprion's CellCarta proteomics discovery platform.
Subscribe to our email newsletter
“This collaboration represents yet another important disease biomarker discovery program for Caprion,” noted Dr Daniel Chelsky, chief scientific officer of Caprion Pharmaceuticals. “This study reflects how Caprion’s biomarker discovery capability addresses many key pharmaceutical needs, including predicting efficacy and safety and managing treatment progression.”
Caprion is also working with Pfizer and Wyeth, who recently expanded collaboration with Caprion to include applications in two clinical trials.